CN1408437A - Microcapsule adrenomedullary cell for curing malignant, tumor pain and its preparing method - Google Patents
Microcapsule adrenomedullary cell for curing malignant, tumor pain and its preparing method Download PDFInfo
- Publication number
- CN1408437A CN1408437A CN02129692A CN02129692A CN1408437A CN 1408437 A CN1408437 A CN 1408437A CN 02129692 A CN02129692 A CN 02129692A CN 02129692 A CN02129692 A CN 02129692A CN 1408437 A CN1408437 A CN 1408437A
- Authority
- CN
- China
- Prior art keywords
- microcapsule
- cell
- adrenomedullary
- aca
- adrenomedullary cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The microcapsule adrenomedullary cell for curing malignant tumor pain consists of ACA microcapsule or APA microcapsule embedded human or animal adrenomedullary cell and the microcapsule entrapped molecular weight is 68-97.4 KD. The microcapsule adrenomedullary cell for curing malignant tumor pain is prepared through five steps of: separation of adrenomedullary cell from human or animal adrenal gland, short period culture in culture liquid, microencapsulation of adrenomedullary cell with ACA or APA, freeze storing in liquid nitrogen and restoring temperature in 37 deg.C before use. The microcapsule adrenomedullary cell for curing malignant tumor pain is transplanted to under human arachnoid of tumor patient to produce obvious pain relieving effect and immune isolation.
Description
Technical field
The present invention relates to a kind of microcapsule adrenomedullary cell that is used for the clinical treatment malignant, tumor pain and preparation method thereof.
Background technology
Press, the sickness rate of malignant tumor is higher and cure rate is lower, and its late result is then poorer.Therefore, chronic pain in various degree all can appear in most of malignant tumor patient late, has a strong impact on patient's life quality.Analgesics such as life-time service morphine not only can make the patient produce dependency, but also can produce serious toxic and side effects; And intrathecal injection morphine expense height not only, and complicated operation, complication takes place easily.Therefore, medical circle is for a long time all in the alternative means of being devoted to seek the clinical treatment malignant, tumor pain.
Therefore studies show that in a large number human or animal's adrenal medullary cell has the function of materials such as catecholamine secretion and enkephalin, can produce analgesic activity when of the same race or xenogenesis adrenal medullary cell being transplanted to people's cavum subarachnoidale.But, no matter be of the same race or the transplanting of xenogenesis adrenal medullary cell, immunological rejection all will take place to donorcells in receptor, and heterogenous cell is transplanted more so.Research also shows, receptor is solved this immunological rejection of the donorcells method that can to adopt immune isolated method be microencapsulation.So-called microencapsulation promptly is the adrenal medullary cell that utilizes suitable semipermeable membrane microcapsule embedding to transplant, and this semipermeable membrane microcapsule only allows small molecular weight material to pass through, and the macromolecule material then is trapped within outside the microcapsule.So, keeping small molecular weight material such as required oxygen of the interior adrenal medullary cell survival of microcapsule and glucose can freely enter in the microcapsule by the microcapsule wall, and the anabolite of capsule inner cells such as catecholamine and enkephalin also can appear capsule and bring into play analgesic activity outward.Macromolecular substances such as receptor immunoglobulin and lymphocyte then can not enter in the microcapsule, therefore can avoid the adrenal medullary cell generation immunological rejection in receptor immune system and the microcapsule.
Summary of the invention
Purpose of the present invention promptly is to provide a kind of emblem capsule adrenal medullary cell that is used for the clinical treatment malignant, tumor pain and preparation method thereof.
To achieve these goals, the present invention utilizes sodium alginate-chitosan-sodium alginate (ACA) microcapsule or sodium alginate-polylysine-sodium alginate (APA) microcapsule embedding human or animal's adrenal medullary cell, to form a kind of ACA or APA emblem capsule adrenal medullary cell.For making anabolites such as small molecular weight material such as oxygen and glucose and catecholamine and enkephalin can freely pass through the microcapsule wall, stop macromolecular substances such as immunoglobulin and lymphocyte to enter in the microcapsule simultaneously, microcapsule molecular cut off (promptly allow pass through maximum molecular weight) should be controlled to be 68-97.4KD.
The preparation method of the microcapsule adrenomedullary cell of above-mentioned treatment malignant, tumor pain comprises separation, cultivation, microencapsulation, frozen and 5 steps of rewarming, promptly at first from adrenal gland's body of human or animal, isolate adrenal medullary cell and cultivate a middle or short term at suitable culture fluid, then with the adrenal medullary cell after ACA or the APA microcapsule embedding short term culture, to form ACA or APA microcapsule adrenomedullary cell and to utilize liquid nitrogen cryopreservation, under 37 ℃ temperature conditions, make frozen microcapsule adrenomedullary cell recovery before the transplanting again.
Enforcement shows, the survival rate height of the emblem capsule adrenal medullary cell of treatment malignant, tumor pain and the function of possessing catecholamine secretion among the present invention, when it is transplanted to malignant, tumor pain patient's cavum subarachnoidale in right amount, significant analgesia role and immune isolation effect can be arranged.
The technical characterictic of the present invention being treated the microcapsule adrenomedullary cell and preparation method thereof of malignant, tumor pain below in conjunction with specific embodiment is described in further detail.
The specific embodiment
The microcapsule adrenomedullary cell of treatment malignant, tumor pain is ACA microcapsule adrenomedullary cell or the APA microcapsule adrenomedullary cell that the adrenal medullary cell by ACA microcapsule or APA microcapsule embedding human or animal forms among the present invention, and its microcapsule molecular cut off is 0.8-97.4KD.For making the microcapsule safe embedding adrenal medullary cell of energy and guaranteeing that microcapsule has good permeability, the diameter of microcapsule can be 250-500 μ m, and encapsulation amount (being the adrenal medullary cell number of each microcapsule embedding) can be (1-8) * 10
2, the microcapsule wall thickness can be 33.1 ± 3.5 μ m, and emblem keed bore dia can be 0.75 ± 0.62 μ m.
The preparation method of microcapsule adrenomedullary cell of treatment malignant, tumor pain mainly comprises 5 steps such as separation, cultivation, microencapsulation, frozen and rewarming among the present invention.(1) separates: at first under aseptic condition, cut adrenal gland's body of human or animal, utilize concentration for the collagenase solution digestion of 0.5-3.0mg/ml and isolate adrenal medullary cell then.(2) cultivate: isolated adrenal medullary cell was cultivated 24-72 hour in the MEM culture fluid, and the survival rate of adrenal medullary cell should be more than 95%.(3) microencapsulation: utilize ACA microcapsule or the embedding of APA microcapsule through the adrenal medullary cell cultivated obtaining ACA or APA microcapsule adrenomedullary cell, and to control its microcapsule diameter be 250-500 μ m, the encapsulation amount is (1-8) * 10
2, the feeble QI cyst wall is thick to be 33.1 ± 3.5 μ m, the microcapsule mesh diameter is 0.75 ± 0.62 μ m.Concrete embedding operating procedure is a prior art, is existing open in the Chinese patent application of 02116987.X at application number, does not repeat them here.(4) frozen: with dimethyl sulfoxine (DMSD) is that ACA or the APA microcapsule adrenomedullary cell of protective agent after with microencapsulation places liquid nitrogen frozen, and the temperature-fall period that cryopreserving liquid is reduced to liquid nitrogen temperature by room temperature should slowly carry out in proper order.(5) rewarming: before the transplanting, frozen microcapsule adrenomedullary cell is recovered under 37 ℃ temperature.
Test shows that the survival rate height of above-mentioned ACA or APA microcapsule adrenomedullary cell is also possessed the catecholamine secretory function.Clinical transplantation shows that above-mentioned ACA or APA microcapsule adrenomedullary cell have significant analgesia role to late malignant tumour pain.Treating the VAS scoring of 34 routine late malignant tumour pain patients, is 8.86 ± 0.94 before the transplanting, and transplanting back three days is 2.36 ± 1.81; The 13 people morphine class medicine (accounting for 38%) of stopping using is arranged after the transplanting, and 16 people's morphine class drug doses reduce (accounting for 47%), and 5 people's morphine class drug doses do not have significant change (accounting for 15%); Transplant among 16 patients that still survived in back 3 months, 8 people's morphine class drug doses still are in the minimizing state, and 8 people need not to use morphine class medicine in addition, transplant 1 patient who still survived in back 5 months and do not use morphine class medicine yet.
In sum as can be known, it is high and possess the catecholamine secretory function that the present invention treats the microcapsule adrenomedullary cell survival rate of malignant, tumor pain, and significant analgesia role and immune isolation effect are arranged when being transplanted to the cavum subarachnoidale of late malignant tumour pain patients.Therefore, the present invention's microcapsule adrenomedullary cell for the treatment of malignant, tumor pain is specially adapted to clinical treatment late malignant tumour pain.
Claims (6)
1. a microcapsule adrenomedullary cell for the treatment of malignant, tumor pain is characterized in that being formed by ACA or APA microcapsule embedding human or animal's adrenal medullary cell, and its microcapsule molecular cut off is 68-97.4KD.
2. the microcapsule adrenomedullary cell of treatment malignant tumor according to claim 1 is characterized in that described microcapsule diameter is 250-500 μ m, and the encapsulation amount is (1-8) * 10
2, the microcapsule wall thickness is 33.1 ± 3.5 μ m, the microcapsule mesh diameter is 0.75 ± 0.62 μ m.
3. the preparation method of the microcapsule adrenomedullary cell of the described treatment malignant tumor of claim 1, it is characterized in that comprising separation, cultivation, microencapsulation, frozen and 5 steps of rewarming, promptly at first from adrenal gland's body of human or animal, isolate adrenal medullary cell and cultivate in culture fluid a middle or short term, form ACA or APA microcapsule adrenomedullary cell and utilize liquid nitrogen cryopreservation with ACA microcapsule or the embedding of APA microcapsule then, under 37 ℃ temperature, make frozen microcapsule adrenomedullary cell recovery before transplanting.
4. the preparation method of the microcapsule adrenomedullary cell of treatment malignant, tumor pain according to claim 3 is characterized in that utilizing in the described separating step concentration for the collagenase solution digestion of 0.5-3.0mg/ml and separate adrenal medullary cell in adrenal gland's body of human or animal.
5. the preparation method of the microcapsule adrenomedullary cell of treatment malignant, tumor pain according to claim 3 is characterized in that in the described incubation step with MEM being culture fluid, and incubation time is 24-72 hour.
6. the preparation method of the microcapsule adrenomedullary cell of treatment malignant, tumor pain according to claim 3 is characterized in that in the described frozen step that with DMSO as the cryopreserving liquid protective agent, cryopreserving liquid is reduced to liquid nitrogen temperature in proper order lentamente by room temperature.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN02129692A CN1408437A (en) | 2002-09-16 | 2002-09-16 | Microcapsule adrenomedullary cell for curing malignant, tumor pain and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN02129692A CN1408437A (en) | 2002-09-16 | 2002-09-16 | Microcapsule adrenomedullary cell for curing malignant, tumor pain and its preparing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1408437A true CN1408437A (en) | 2003-04-09 |
Family
ID=4746331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN02129692A Pending CN1408437A (en) | 2002-09-16 | 2002-09-16 | Microcapsule adrenomedullary cell for curing malignant, tumor pain and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1408437A (en) |
-
2002
- 2002-09-16 CN CN02129692A patent/CN1408437A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aebischer et al. | Transplantation in humans of encapsulated xenogeneic cells without immunosuppression: a preliminary report | |
| US7041504B2 (en) | Cancer cell-inhibiting culture medium produced by culturing restricted entrapped cancer cells | |
| JP3291297B2 (en) | Bioartificial endocrine device | |
| Date et al. | Grafting of encapsulated dopamine-secreting cells in Parkinson's disease: long-term primate study | |
| CN101466360A (en) | Multi-membrane immunoisolation system for cellular transplant | |
| Lysaght et al. | Encapsulated cells as therapy | |
| CN105543168A (en) | Method for preserving and transporting immune cells | |
| Christenson et al. | Biomedical applications of immobilized cells | |
| ES2206696T3 (en) | IMPLANTABLE AGAROSA-COLAGEN PEARLS CONTAINING CELLS THAT PRODUCE A DIFUNDIBLE BIOLOGICAL PRODUCT, AND ITS USES. | |
| Theodorou et al. | Problems in the use of polycarbonate diffusion chambers for syngeneic pancreatic islet transplantation in rats | |
| CN1057445C (en) | Method for preparing anticancer bioactive peptide preparation | |
| US7297331B2 (en) | Beads containing restricted cancer cells producing material suppressing cancer cell proliferation | |
| Kobayashi | Bioartificial pancreas for the treatment of diabetes | |
| CN1408437A (en) | Microcapsule adrenomedullary cell for curing malignant, tumor pain and its preparing method | |
| WO2000078295A1 (en) | Microencapsulated bovine adrenal medulla chromaffin cell-drug for alleviating pain | |
| CN110279717A (en) | The preparation of crocodile first active principle and its anti-oxidant, anti-hepatic fibrosis application | |
| Sale et al. | Stem cell regions in filiform papillae of tongue as targets of graft-versus-host disease | |
| CN100591360C (en) | New application of chromaffin cell of adrenal medulla or opium peptide energy cell | |
| CA2034641A1 (en) | Homologous guluronic acid alginate coating composition for in-vivo application and implatation and method of using same | |
| Iwata et al. | Bioartificial pancreas research in Japan | |
| CN101069743B (en) | Use of inactive BCG vaccine in preparation of use for treatment of allergic action diseases | |
| CN1127948C (en) | Microencapsulated bovine adrenal medulla chromaffin cell-drug for alleviating pain | |
| Friedman | Toward a hybrid artificial pancreas | |
| CN108236613A (en) | Realgar microorganism extracting liquid is preparing the application in inhibiting angiogenesis drug | |
| CN101152168A (en) | Isoliquirtigenin capsule for treating gastrospasm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |